Clinical Trial Results Show Evidence That Early Alzheimer’s Can Be Reversed
Clinical Trial Results
Evidence That Early Alzheimer’s Can Be Reversed
Pharmaceutical trials for Alzheimer’s have failed repeatedly, but a new study, using a fundamentally different approach based upon the science of Dale Bredesen, M.D., has provided the first clinical trial success: using precision medicine to identify and target the drivers of Alzheimer’s or pre-Alzheimer’s in each patient. Dr. Bredesen and his team have posted exciting, positive results in medRxiv, the Yale-backed site for health sciences.
Until now, therapeutic development for Alzheimer’s disease has been almost uniformly unsuccessful, with over 400 failed clinical trials. The few “successes” (e.g., memantine) have not offered sustained improvement. For example, the recent claim of a positive trial for the drug candidate donanemab did not show cognitive improvement, nor even stabilization of dementia, but merely reduced the rate of progression by about one-third. Arguably, the greatest failure of medical treatments to date is in neurodegenerative diseases like Alzheimer’s and Lou Gehrig’s disease; about 45 million Americans are projected to die from Alzheimer’s if effective treatment and prevention are not developed.
Posted in medRxiv, the study, entitled Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial, used deeper dives into each patient’s genetics and biomarkers in order to derive the optimal personalized, precision medicine protocol for each. The study was led by three integrative physicians — Drs. Kat Toups, Ann Hathaway, and Deborah Gordon —along with Dr. Bredesen.
Their proof-of-concept trial included 25 participants, aged 50 to 76, all with MCI (pre-Alzheimer’s) or early-stage dementia. Each patient was assessed for multiple potential contributors — inflammation, insulin resistance, nutrient and hormonal deficiencies, specific pathogens, toxicants, and biotoxins, as well as genetics — then treated with a personalized protocol that was continued for nine months. This is the same approach used by Apollo Health, which has developed software and programs to optimize the precision medicine protocol for cognitive decline. Addressing the presumptive root causes of the cognitive decline with this type of functional medicine approach has previously led to publications of anecdotal “case study” improvements, including Reversal of Cognitive Decline: 100 Patients, but this is the first prospective clinical trial.
Cognitive testing revealed that among the study participants, 21 improved (84%), one showed no change (4%), and three declined (12%). Cognitive assessments included MoCA (Montreal Cognitive Assessment), CNS Vital Signs (an online, quantitative, multi-domain neuropsychological battery), BrainHQ (computerized brain training and assessment), AQ-21 (Alzheimer’s Caregiver Assessment Questionnaire), and AQ-20, a caregiver measurement-of-change rating scale. MRI brain imaging complemented the cognitive testing and showed that the brain shrinkage that typically occurs with MCI and dementia was prevented.
These strongly positive results support the view that identifying and treating the contributors to cognitive decline for each patient, with a personalized protocol, represents an effective treatment approach for patients with MCI or early dementia. The report concluded that a larger, randomized controlled trial is warranted, and this follow-up study is already in the works. The results reported by the group offer genuine hope to the millions of people with dementia or mild cognitive impairment, as well as those at risk due to family histories of dementia.
Co-authors included Kat Toups, M.D.; Ann Hathaway, M.D.; Deborah Gordon, M.D.; Cyrus Raji, M.D.; Sharon Hausman-Cohen, M.D.; Henrianna Chung; Alan Boyd; Benjamin Hill, Ph.D.; Mouna Attarha, Ph.D.; Won Jong Chwa; Michael Jarrett, Ph.D.; and Dale Bredesen, M.D. This study was supported with funding by the Four Winds Foundation, performed in collaboration with QuesGen Systems, Inc. CRO. Dr. Bredesen is a consultant for Apollo Health, which was not involved in the funding, planning, execution, analysis, or publication of the trial.
Discussion About the Trial
Please watch as Dr. Bredesen and Apollo Health’s Chief Health Liaison Julie Gregory met with Dr. Kat Toups to discuss the recently published study. You can find a transcript of the discussion here.
ReCODE Protocol Analysis
Building upon the clinical trial and research of Dr. Bredesen, we are pleased to announce our first peer-reviewed analysis of data from 255 participants in our ReCODE program in the scientific journal Biomedicines. The results of this analysis showed that 74% of the participants’ cognition was either stabilized or improved.
The Bredesen Protocol is based on over three decades of Dr. Bredesen’s laboratory research, resulting in hundreds of peer-reviewed publications that have uncovered the biochemical mechanisms behind the erosion of memory associated with Alzheimer’s disease. For anyone who would like to learn more about Dr. Bredesen’s science, click on the button below.
We support physicians, other medical professionals, lifestyle, and nutrition experts by providing dynamic, evolving solutions for cognitive decline, empowering practitioners both to prevent and reverse symptoms. Practitioners who are interested in learning how to use the Bredesen Protocol, click on the button below.
Apollo Health is building the first-ever brain health community around the prevention and reversal of cognitive decline; providing you the resources to build the care team you need, which might consist of a lead physician, a health coach, a nutritionist, and your choice of many additional specialists with all of the tools and resources necessary for success. For anyone interested in learning more about the Bredesen Protocol, click on the button below.